Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Capital Expenditures (2016 - 2025)

Bio-Techne has reported Capital Expenditures over the past 17 years, most recently at $5.9 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $5.9 million for Q4 2025, down 13.19% from a year ago — trailing twelve months through Dec 2025 was $26.3 million (down 47.84% YoY), and the annual figure for FY2025 was $31.0 million, down 50.69%.
  • Capital Expenditures for Q4 2025 was $5.9 million at Bio-Techne, up from $5.4 million in the prior quarter.
  • Over the last five years, Capital Expenditures for TECH hit a ceiling of $18.0 million in Q2 2024 and a floor of $4.9 million in Q2 2025.
  • Median Capital Expenditures over the past 5 years was $10.4 million (2021), compared with a mean of $10.5 million.
  • Biggest five-year swings in Capital Expenditures: surged 143.31% in 2023 and later plummeted 72.8% in 2025.
  • Bio-Techne's Capital Expenditures stood at $10.2 million in 2021, then crashed by 39.92% to $6.1 million in 2022, then soared by 143.31% to $14.9 million in 2023, then tumbled by 54.11% to $6.8 million in 2024, then dropped by 13.19% to $5.9 million in 2025.
  • The last three reported values for Capital Expenditures were $5.9 million (Q4 2025), $5.4 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.